Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Jacobsen

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Transplantation and Cellular Therapy|October 20, 2021
Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with LymphomaReid W Merryman, Robert Redd, Erin Jeter, et al.
Hemasphere|January 30, 2023
Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular LymphomaReid W Merryman, Laure Michaud, Robert Redd, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2017
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for LymphomaChristopher J Gibson, R Coleman Lindsley, Vatche Tchekmedyian, et al.
Blood Advances|November 18, 2022
Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantationReid W Merryman, Robert A Redd, Eleanor Taranto, et al.
British Journal of Haematology|August 4, 2017
Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysisAbraham S Kanate, Alyssa DiGilio, Kwang W Ahn, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 14, 2018
NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018Steven M Horwitz, Stephen M Ansell, Weiyun Z Ai, et al.
Blood|October 15, 2021
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomasAlison J Moskowitz, Paola Ghione, Eric Jacobsen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 8, 2020
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020Neha Mehta-Shah, Steven M Horwitz, Stephen Ansell, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 5, 2020
NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021Steven M Horwitz, Stephen Ansell, Weiyun Z Ai, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 11, 2022
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in OncologySteven M Horwitz, Stephen Ansell, Weiyun Z Ai, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Transplantation and Cellular Therapy|October 20, 2021
Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with LymphomaReid W Merryman, Robert Redd, Erin Jeter, et al.
Hemasphere|January 30, 2023
Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular LymphomaReid W Merryman, Laure Michaud, Robert Redd, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2017
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for LymphomaChristopher J Gibson, R Coleman Lindsley, Vatche Tchekmedyian, et al.
Blood Advances|November 18, 2022
Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantationReid W Merryman, Robert A Redd, Eleanor Taranto, et al.
British Journal of Haematology|August 4, 2017
Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysisAbraham S Kanate, Alyssa DiGilio, Kwang W Ahn, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 14, 2018
NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018Steven M Horwitz, Stephen M Ansell, Weiyun Z Ai, et al.
Blood|October 15, 2021
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomasAlison J Moskowitz, Paola Ghione, Eric Jacobsen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 8, 2020
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020Neha Mehta-Shah, Steven M Horwitz, Stephen Ansell, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 5, 2020
NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021Steven M Horwitz, Stephen Ansell, Weiyun Z Ai, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 11, 2022
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in OncologySteven M Horwitz, Stephen Ansell, Weiyun Z Ai, et al.
Pageof 7